Cardium’s LifeAgain Signs Commercialization Agreement with AgencyONE [Health & Beauty Close – Up]

Cardium Therapeutics announced that its LifeAgain Insurance Solutions Inc., a subsidiary in Cardium's investment portfolio, has entered into a commercialization agreement with AgencyONE to support the development and commercialization of survivable risk life insurance products based on Cardium's advanced medical data analytics platform technology (ADAPT).

LifeAgain Insurance Solutions, Inc. is a newly-formed medical data analytics business that has been internally developed by researchers at Cardium. LifeAgain is initially focused on the development, marketing and sale of survivable risk term life insurance programs for patients with certain cancers or other medical conditions having improved mortality due to medical advancements, but who are typically considered uninsurable based on traditional life insurance underwriting standards.

According to a release, working in cooperation with life insurance companies, LifeAgain seeks to use the power of its proprietary medical data analytics technology in the field of life insurance to: (1) apply medically-driven algorithms and other quantitative tools to support Decision Rule Adaption to broaden eligibility for individuals with specific medical conditions; (2) more deeply assess individualized mortality using the prognostic value of advanced medical diagnostic information that is supported by long-term clinical studies, peer-reviewed publications and physician consensus; and (3) establish customized policy premium pricing in a scalable manner operating within the life insurance industry's established actuarial underwriting practices and standard operating procedures, and designed to monetize medical advancements in prostate cancer mortality.

LifeAgain's initial product platform will be centered on Cardium's BlueMetric Select term life insurance program which has been specifically designed for eligible men with active localized prostate cancer. This term life insurance program is expected to represent a product offering specifically developed for individuals with active cancer based on risk assessments using Cardium's advanced medical data analytics. LifeAgain's BlueMetric Select product may be marketed and sold under other trade names by LifeAgain's potential strategic partners in the U.S. and international markets. The Company has developed intellectual property as it relates to its advanced medical data analytics technology for life insurance underwriting and risk assessment.

AgencyONE, a full-service life insurance brokerage general agency (BGA) located in Bethesda, MD, will be the sole BGA providing insurance industry expertise, underwriting and case management services for LifeAgain's BlueMetric Select.

LifeAgain is a newly-formed advanced medical data analytics platform technology (ADAPT) business that is focused on furthering the development, marketing and sale of "survivable risk" ten-year level term life insurance programs for cancer survivors or others with medical conditions that are currently considered uninsurable based on traditional underwriting standards.

More Information:

http://www.cardiumthx.com/lifeagain

http://www.agencyone.net

http://www.cardiumthx.com

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations.

((Comments on this story may be sent to newsdesk@closeupmedia.com))